Alnylam Pharmaceuticals Inc (ALNY)

42.27
1.50 3.60
NASDAQ : Health Care
Prev Close 40.80
Open 41.29
Day Low/High 41.11 / 43.58
52 Wk Low/High 49.96 / 136.02
Volume 638.67K
Avg Volume 1.72M
Exchange NASDAQ
Shares Outstanding 85.81M
Market Cap 3.46B
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors

Alnylam Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced new positive results from its ongoing Phase 2 open-label extension (OLE) study with fitusiran, an investigational RNAi...

Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors

Alnylam Reports Positive Interim Phase 1 Results For Fitusiran In Hemophilia A And B Patients With Inhibitors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran, an investigational RNAi...

Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Reports Positive Initial Clinical Activity Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive initial results from Cohorts 1 and 2 of Part C of its Phase 1 study with givosiran (gi-VOH-si-ran), the...

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company And Alnylam Pharmaceuticals Present Positive Results From ORION-1 Phase 2 Study Of Inclisiran (formerly PCSK9si)

The Medicines Company (Nasdaq:MDCO) and Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision For Co-Development And Co-Commercialization Of Fitusiran In Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company today announced that, pursuant to the companies' global alliance signed in January 2014, Sanofi Genzyme elected to opt in to co-develop...

Http://www.themedicinescompany.com/

Http://www.themedicinescompany.com/

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam To Present New Clinical Results At 58th Annual Meeting Of The American Society Of Hematology (ASH)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present new results from clinical studies of three of its...

Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2016, and highlighted recent progress in advancing its pipeline.

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 25 th Annual Credit...

Alnylam To Webcast Conference Call Discussing Third Quarter 2016 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2016 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter on Wednesday, November 2, 2016, after the U.

Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation

Alnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation

Alnylam Pharmaceuticals' (ALNY) phase III trial for its patisiran drug was recommended to continue by the trial's data monitoring committee.

Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)

Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR...

Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades

Alnylam Pharmaceuticals (ALNY) Stock Lower as Drug Development Stopped, Downgrades

Alnylam Pharmaceuticals (ALNY) ended production of a key drug yesterday, prompting Morgan Stanley to cut its rating on the stock earlier today.

Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More

Analysts' Actions -- Advanced Micro, Alnylam, Gap, Fifth Third and More

Here are Friday's top research calls, including downgrades for Fifth Third and Alnylam, an upgrade for Gap and new coverage of Advanced Micro Devices.

Stocks Barely Budge as Wall Street Waits for Friday's Jobs Report

Stocks Barely Budge as Wall Street Waits for Friday's Jobs Report

Stocks stay close to the flatline on Thursday as Wall Street waits for the release of the monthly U.S. jobs report on Friday.

Alnylam Pharmaceuticals Shares Plunge After Halting Drug Development

Alnylam Pharmaceuticals Shares Plunge After Halting Drug Development

The biopharmaceutical company sparked a sharp selloff after halting production on a key drug.

Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report

Stocks Hold Mixed as Crude Settles Above $50, Wall Street Eyes Jobs Report

Stocks hold mixed on Thursday afternoon as crude oil enjoys another rally and Wall Street looks toward the Friday release of the monthly jobs report.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Alnylam Pharmaceuticals, Inc. And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Securities Fraud Violations By Alnylam Pharmaceuticals, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Alnylam Pharmaceuticals, Inc.

Stocks Extend Declines as Twitter Shares Sag

Stocks Extend Declines as Twitter Shares Sag

Stocks hold lower on Thursday as Twitter suffers its worst day since April 2015.

Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded

Alnylam Pharma (ALNY) Stock Tumbles on Discontinued Drug, Downgraded

Alnylam Pharmaceuticals (ALNY) stopped development of one of its two gene-silencing drugs and was subsequently downgraded at several firms this morning.

Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector

Alnylam Gene-Silencing Drug Blows Up; Damage Could Spread Deep Into Biotech Sector

Alnylam said Wednesday evening that it was scrapping development of revusiran, one of the two most advanced gene-silencing drugs in the company's pipeline.

Stock Futures Edge Lower as Jobless Claims Fall

Stock Futures Edge Lower as Jobless Claims Fall

Stock futures edge lower on Thursday in a quieter session ahead of Friday's U.S. jobs report.

Analysts' Actions -- Alnylam, AutoNation, Tesla and More

Analysts' Actions -- Alnylam, AutoNation, Tesla and More

Here are Thursday's top research calls, including an upgrade for AutoNation and downgrades for Alnylam and Tesla.

Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development

Alnylam Pharma (ALNY) Stock Plunges in After-Hours Trading, Stops Revusiran Development

Alnylam Pharma (ALNY) has stopped the development of its drug revusiran to treat hereditary amyloidosis with cardiomyopathy.

Alnylam Pharmaceuticals Discontinues Revusiran Development

Alnylam Pharmaceuticals Discontinues Revusiran Development

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the...